Serina Therapeutics, Inc. is the only company in the world to develop polyoxazoline polymers for pharmaceutical applications. POZ polymers are multifunctional and can be coupled to known drugs, creating novel therapeutics to dramatically alter pharmacokinetics. Molecules that normally have short duration times in the body can be converted to molecules with prolonged activity – sometimes as long as weeks. This prolonged half-life in the body may improve the safety and efficacy of the molecule. In addition, Serina has developed technology that allows the resulting polymer drug to be specifically targeted to receptors on the surface of cancer cells. This approach may also be useful for applications outside oncology.